Merck to Buy Schering-Plough for $41.1 Billion
By REUTERS Filed at 6:15 a.m. ET
By REUTERS Filed at 6:15 a.m. ET
NEW YORK (Reuters) - Merck (NYSE:MRK) & Co Inc said Monday that it would acquire Schering-Plough (NYSE:SGP PRB) (NYSE:SGP) Corp for $41.1 billion, uniting the makers of cholesterol drugs Zetia and Vytorin, in the second megadeal for Big Pharma in weeks. The two New Jersey-based drugmakers, which announced significant job cuts last fall, have been striving to become more efficient amid setbacks to Vytorin and Zetia, whose combined fourth-quarter sales slumped 26 percent.